Hepatitis C virus genotypes in Adana and Antakya regions of Turkey

Key Findings & Data:Materials and methods: The study consisted of 639 HCV-RNA–positive patients with chronic HCV infection in Adana (214 males and 101 females) and Antakya (139 males and 185 females) in Turkey.

💡

Conclusion & Impact:Conclusion: Rates of genotypes 2 and 3 were unexpectedly high in Adana compared to other parts of Turkey.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Key words: Hepatitis C · genotypes · Adana

Abstract

Hepatitis C virus (HCV) genotype 1 was found to be dominant in Turkey. In this study, HCV genotypes were examined in the Adana and Antakya regions of Turkey. Materials and methods: The study consisted of 639 HCV-RNA–positive patients with chronic HCV infection in Adana (214 males and 101 females) and Antakya (139 males and 185 females) in Turkey. Real time-polymerase chain reaction was used for genotype determination. Results: In Antakya, it was determined that the percentages of genotypes of type 1a (0.31%), 1b (86.73%), 2 (9.26%), 3 (0.93%), and 4 (2.78%) were compatible with the nationwide results seen in Turkey. In Adana, the percentages of genotypes of type 1a (3.49%), 1b (55.24%), 2 (14.60%), 3 (26.03%), and 4 (0.63%) were found to be different. This difference was mainly due to the infection rates in males: genotype 1b was significantly lower (42.5% versus 82.2%, P < 0.001) in men in Adana, but genotype 2 (17.8% versus 7.9%, P = 0.021) and genotype 3 (34.6% versus 7.9%, P < 0.001) were significantly higher in men than in women in Adana. Conclusion: Rates of genotypes 2 and 3 were unexpectedly high in Adana compared to other parts of Turkey.

Özet

Hepatitis C virus (HCV) genotype 1 was found to be dominant in Turkey. In this study, HCV genotypes were examined in the Adana and Antakya regions of Turkey. Materials and methods: The study consisted of 639 HCV-RNA–positive patients with chronic HCV infection in Adana (214 males and 101 females) and Antakya (139 males and 185 females) in Turkey. Real time-polymerase chain reaction was used for genotype determination. Results: In Antakya, it was determined that the percentages of genotypes of type 1a (0.31%), 1b (86.73%), 2 (9.26%), 3 (0.93%), and 4 (2.78%) were compatible with the nationwide results seen in Turkey. In Adana, the percentages of genotypes of type 1a (3.49%), 1b (55.24%), 2 (14.60%), 3 (26.03%), and 4 (0.63%) were found to be different. This difference was mainly due to the infection rates in males: genotype 1b was significantly lower (42.5% versus 82.2%, P < 0.001) in men in Adana, but genotype 2 (17.8% versus 7.9%, P = 0.021) and genotype 3 (34.6% versus 7.9%, P < 0.001) were significantly higher in men than in women in Adana. Conclusion: Rates of genotypes 2 and 3 were unexpectedly high in Adana compared to other parts of Turkey.

Keywords

Key words: Hepatitis C genotypes Adana Antakya Turkey

🔖

Cite This Article

ÖZTÜRK, A. B., DOĞAN, Ü. B., ÖZTÜRK, N. A. (2014). Hepatitis C virus genotypes in Adana and Antakya regions of Turkey. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 4, 661–665. https://ajindex.com/articles/220667

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (10)

World Health Organization. Hepatitis C fact sheet. Geneva, Switzerland: WHO; 2014. Available at http://www.who.int/ mediacentre/factsheets/fs164/en/. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–538.
Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 1999; 3: 693–716.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558–567.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962–973.
Abacioglu YH, Davidson F, Tuncer S, Yap PL, Ustacelebi S, Yulug N, Simmonds P. The distribution of hepatitis C virus genotypes in Turkish patients. Viral Hepatit J 1995; 2: 297–301.
Erensoy S, Goksel S, Akarca US, Ozkahya M, Canatan D. Genotyping of hepatitis C virus by direct sequence analysis of polymerase chain reaction products. Flora 2002; 7: 104–111.
Bozdayı G, Rota S, Verdi H, Derici Ü, Sindel Ş, Bali M, Başay T. Investigation of the presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotypes. Mikrobiyol Bul 2002; 36: 291–300 (article in Turkish with an abstract in English). Bozdayi AM, Aslan N, Bozdayi G, Türkyilmaz AR, Sengezer T, Wend U, Erkan O, Aydemir F, Zakirhodjaev S, Orucov S et al. Molecular epide miology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149: 2115–2129.
Selcuk H, Kanbay M, Korkmaz M, Gur G, Akcay A, Arslan H, Ozdemir N, Yilmaz U, Boyacioglu S. Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment. Dig Dis Sci 2006; 51: 1420–1425.
Çil T, Özekinci T, Göral V, Altıntaş A. Hepatitis C virus genotypes in the southeast region of Turkey. Türkiye Klinikleri J Med Sci 2007; 27: 496–500 (article in Turkish with an abstract in English). Kalaycı R, Altındiş M, Gülamber C, Demirtürk N, Akcan Y, Demi